Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22233159 | 0.80 | SYK (0.46) | L3MBTL1LMNAMEN1KMT2ANPC1 | |
| Trifluoroacetic Acid SCHEMBL22233162 | 0.80 | MEN1 (0.44) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL25532258 | 0.78 | LMNA (0.48) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL25532256 | 0.77 | LMNA (0.47) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL6203374 | 0.77 | CTSL (0.51) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL7841236 | 0.75 | MEN1 (0.53) | L3MBTL1MAPTLMNAMEN1KMT2A | |
| SCHEMBL6191239 | 0.75 | MEN1 (0.48) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL4861073 | 0.71 | SMN1; SMN2 (0.58) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL6187228 | 0.71 | ITGB3 (0.51) | L3MBTL1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6044415 | 0.69 | SMN1; SMN2 (0.51) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| EP-3911644-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150385-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | L3MBTL1 1507/4885MAPT 4367/4885LMNA 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.